Jonathan W. Goldman
University of Colorado Cancer Center(US)UCLA Jonsson Comprehensive Cancer CenterUniversity of Colorado Denver(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Cancer Immunotherapy and Biomarkers, Peptidase Inhibition and Analysis, Neuroendocrine Tumor Research Advances
Most-Cited Works
- → Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer(2015)6,155 cited
- → Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial(2019)2,108 cited
- → Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer(2020)1,691 cited
- → Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial(2017)1,074 cited
- → Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study(2016)952 cited
- → Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors